Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy

doi:10.5306/wjco.v16.i12.115789

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (69)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=47

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=15

Dec 24, 2025 (publication date) through Dec 29, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Oncol. Dec 24, 2025; 16(12): 115789
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.115789

Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy

Abdellatif Bouayad

Abdellatif Bouayad, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Oujda-Angad 60049, Oriental, Morocco

Author contributions: Bouayad A wrote, designed, and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Abdellatif Bouayad, MD, Associate Professor, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr

Received: October 27, 2025
Revised: October 30, 2025
Accepted: November 20, 2025
Published online: December 24, 2025
Processing time: 59 Days and 6.4 Hours

Core Tip

Core Tip: Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) has dual effects on cancer development and progression, influencing immune surveillance and immune evasion through tumor microenvironment modulation. It serves as a promising novel molecular biomarker for prognosis and for predicting cancer therapy responses. Furthermore, ENTPD6-derived neopeptide vaccines, as well as adoptive T-cell transfer using T cells engineered with T-cell receptors targeting ENTPD6, may constitute promising strategies in cancer immunotherapy.